Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influenza Vaccine, Formulation 2008-2009 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Influenza Vaccine, Formulation 2008-2009 | BIOLOGICAL | 1 dose of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009 |
Inclusion Criteria: * Subjects eligible for enrollment into this study are male and female adults who are: 1. ≥ 18 years of age, mentally competent, willing and able to give informed consent prior to study entry 2. able to comply with all study requirements 3. in good health as determined by...
Influenza Vaccine, Formulation 2008-2009 is an investigational vaccine being developed for the prevention of influenza, including seasonal influenza. It is designed to elicit an immune response against the influenza virus strains included in the 2008-2009 formulation. The vaccine is intended for use in various age groups, including children, adults, and the elderly.
Influenza Vaccine, Formulation 2008-2009 is being developed by Novartis AG, a multinational pharmaceutical company. Novartis is publicly traded on the New York Stock Exchange under the ticker symbol NVS. The company has conducted clinical trials to evaluate the safety and immunogenicity of this seasonal influenza vaccine formulation.
Influenza Vaccine, Formulation 2008-2009 is in Phase 2 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. The development program includes completed Phase 2 and Phase 3 trials, but the overall program is currently categorized as Phase 2, with no active trials ongoing.
Influenza Vaccine, Formulation 2008-2009 has been studied in three completed clinical trials. These include NCT00310648, a Phase 3 trial in elderly subjects in China; NCT00316628, a Phase 2 trial in adults aged 65 and over in Italy; and NCT00408395, a Phase 2 trial in children in Finland. A fourth trial, NCT00748813, evaluated the 2008/2009 strain composition in healthy adults.
Influenza Vaccine, Formulation 2008-2009 works by presenting inactivated influenza virus surface antigens to the immune system. This exposure triggers the production of antibodies that recognize and neutralize the specific influenza virus strains included in the vaccine formulation. The vaccine is designed to provide protection against seasonal influenza infection by priming the immune system to respond rapidly upon exposure.